{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:21:17Z","timestamp":1790673677681,"version":"4.1.0"},"reference-count":152,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) are anti\u2010cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in a fixed dose, although large interpatient pharmacokinetic (PK) variability is described. For imatinib, sunitinib and pazopanib exposure\u2010treatment outcome (efficacy and toxicity) relationships have been established and therapeutic windows have been defined, therefore dose optimization based on the measured blood concentration, called therapeutic drug monitoring (TDM), can be valuable in increasing efficacy and reducing the toxicity of these drugs.<\/jats:p>\n                  <jats:p>In this review, an overview of the current knowledge on TDM guided individualized dosing of imatinib, sunitinib and pazopanib for the treatment of solid tumours is presented. We summarize preclinical and clinical data that have defined thresholds for efficacy and toxicity. Furthermore, PK models and factors that influence the PK of these drugs which partly explain the interpatient PK variability are summarized. Finally, pharmacological interventions that have been performed to optimize plasma concentrations are described. Based on current literature, we advise which methods should be used to optimize exposure to imatinib, sunitinib and pazopanib.<\/jats:p>","DOI":"10.1111\/bcp.14185","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T21:08:27Z","timestamp":1574975307000},"page":"258-273","source":"Crossref","is-referenced-by-count":76,"title":["Imatinib, sunitinib and pazopanib: From flat\u2010fixed dosing towards a pharmacokinetically guided personalized dose"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3512-4671","authenticated-orcid":false,"given":"Kim","family":"Westerdijk","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.E.","family":"Desar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Radboud University Medical Center  Nijmegen the Netherlands"},{"name":"Department of Medical Oncology Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-178X","authenticated-orcid":false,"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Dutch Pharmacology and Oncology Group (DPOG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044389"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11593320-000000000-00000"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918818347"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2596"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2194"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2740"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0443-y"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.503"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.045666"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1170-y"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4818"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3463-x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13327"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544020-00002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197709222971203"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.09.015"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2016.0880"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077169"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5362"},{"key":"e_1_2_7_24_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Crizotinib clinical pharmacology and biopharmaceutics review(s).2011 March30 [Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202570Orig1s000ClinPharmR.pdf."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-015-0375-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1255"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.09.007"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.787"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544090-00001"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_7_31_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Imatinib clinical pharmacology and biopharmaceutics review. 2000 [Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-335S001_Gleevec_BioPharmr_P1.pdf."},{"key":"e_1_2_7_32_1","unstructured":"European Medicines Agency CfMPfHUC. Imatinib summary of product characteristics. 2013 [Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imatinib-accord-epar-product-information_en.pdf."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16014"},{"issue":"1","key":"e_1_2_7_35_1","first-page":"139","article-title":"Abl protein\u2010tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c\u2010kit and platelet\u2010derived growth factor receptors","volume":"295","author":"Buchdunger E","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.925"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20652"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604355"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0439-7"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.12.029"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.01.007"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1302-7"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-014-0349-2"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.7_suppl.345"},{"issue":"18","key":"e_1_2_7_45_1","first-page":"30734","article-title":"Exploratory investigation of target Pazopanib concentration range for patients with renal cell carcinoma","volume":"7","author":"Noda S","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2652"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12007"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0490"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17098-0"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2099"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.030"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4284"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy095"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_7_59_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) EMA. Imatinib assessment report 2013 [Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/glivec-h-c-406-ii-0080-epar-assessment-report-variation_en.pdf."},{"key":"e_1_2_7_60_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) EMA. Sunitinib assessment report 2019 [Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/sutent-h-c-687-ii-0070-epar-assessment-report-variation_en.pdf."},{"key":"e_1_2_7_61_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Sunitinib clinical pharmacology and biopharmaceutics review. 2006 [Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021938_S000_Sutent_BioPharmR.pdf."},{"issue":"5","key":"e_1_2_7_62_1","first-page":"471","article-title":"SU11248 inhibits KIT and platelet\u2010derived growth factor receptor beta in preclinical models of human small cell lung cancer","volume":"2","author":"Abrams TJ","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"e_1_2_7_63_1","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet\u2010derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel DB","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.29"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.02.011"},{"key":"e_1_2_7_66_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) EMA. Sunitinib summary of product characteristics 2019 [Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sutent-epar-product-information_en.pdf."},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2322-7"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2574"},{"issue":"18","key":"e_1_2_7_69_1","first-page":"30603","article-title":"The alternative 2\/1 schedule of Sunitinib is superior to the traditional 4\/2 schedule in patients with metastatic renal cell carcinoma: a meta\u2010analysis","volume":"21","author":"Sun Y","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0137-2"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12163"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-007-0007-2"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6994"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609329103"},{"key":"e_1_2_7_78_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Pazopanib clinical pharmacology and biopharmaceutics review(s).2008 December19 [Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_ClinPharmR.pdf."},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262101"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.055574"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1398"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0917-1"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2012.734642"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02719.x"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02117.x"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0304-9"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0741-6"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0346"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.01.014"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1225038"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004283"},{"key":"e_1_2_7_93_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency. Pazopanib assessment report. 2010 June 14."},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200603000-00015"},{"issue":"9","key":"e_1_2_7_95_1","first-page":"LB\u2010354","article-title":"A phase I mass\u2010balance study to evaluate the metabolism and excretion of sunitinib (SU11248) in healthy male subjects","volume":"67","author":"Bello C","year":"2007","journal-title":"Cancer Res"},{"key":"e_1_2_7_96_1","first-page":"1","article-title":"Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia","volume":"20","author":"Natarajan H","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12550"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9633-5"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0876-0"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02372.x"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0950"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0730-x"},{"issue":"2","key":"e_1_2_7_103_1","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa Y","year":"2011","journal-title":"Ther Drug Monit"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.953"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100201"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3819"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030603"},{"issue":"10","key":"e_1_2_7_108_1","first-page":"019","article-title":"Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors","volume":"4","author":"Verboom MC","year":"2019","journal-title":"Pharmacogenomics J"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3445"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0441-0"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5785"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1159\/000493195"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.4390"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1893"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0111-4"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000025"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0404-5"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3104-9"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23881"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0178-2"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.47"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0144"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70266-2"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.04.018"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1367-0"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1213-4"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009347868"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000141"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2455-3"},{"key":"e_1_2_7_130_1","unstructured":"BaneyxG CombesFP HuangPH ElmeliegyM. Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma 2017 [Available from:https:\/\/www.page-meeting.org\/default.asp?abstract=7105."},{"issue":"10","key":"e_1_2_7_131_1","first-page":"018","article-title":"Impact of CYP3A4 22 on Pazopanib pharmacokinetics in cancer patients","volume":"27","author":"Bins S","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.199"},{"key":"e_1_2_7_133_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3214"},{"key":"e_1_2_7_134_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency. Pazopanib summary of product characteristics. 2013 [Available from:https:\/\/www.ema.europa.eu\/documents\/product-information\/votrient-epar-product-information_en.pdf."},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2164-3"},{"issue":"10","key":"e_1_2_7_136_1","first-page":"019","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"7","author":"Groenland SL","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.194"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5043-9"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1515"},{"key":"e_1_2_7_140_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.3119"},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.2560"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13333"},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.05.004"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw182"},{"key":"e_1_2_7_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1902-3"},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr343"},{"key":"e_1_2_7_147_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2001.00063.x"},{"issue":"10","key":"e_1_2_7_148_1","first-page":"018","article-title":"Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma","volume":"5","author":"Reimers MA","year":"2018","journal-title":"Invest New Drugs"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0578"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2748"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9725-2"},{"key":"e_1_2_7_152_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_7_153_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13882"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T09:10:51Z","timestamp":1694077851000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":152,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/bcp.14185"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14185","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]}}}